Drs. Campochiaro and Nguyen are highly respected in the field, but they have a reputation as proponents of “underdog” treatments on the fringe. They were investigators in OXGN’s AMD program at Hopkins that went nowhere.
I would not assume that AdPEDF is going to be a serious competitor to Lucentis because these gentlemen are on board. To the contrary, it seems as though GNVC may be softening its commitment to AdPEDF; they talk about it less and less on their investor CCs. Regards, Dew
Market Data 
Markets 
AI
